Abstracts tagged "Inflammation"

Abstract Number: 2044 • ACR Convergence 2025
Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis
Oyku Zeynep Avarbek¹, Ozlem Arikan², Aysu Tatari³, Furkan Ak⁴, Bengisu Gur⁵, Sinem Nursel Duzenci⁶, Yasin Taha Tuncar⁷, Mustafa Sivri⁸, Mustafa Ovayolu⁹ and Miray Kurtca¹⁰, ¹Bezmialem Vakif University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ²Istanbul Aydin University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ³Pamukkale University, Faculty of Medicine, Denizli, Türkiye, Denizli, Turkey, ⁴Sofia University St. Kliment Ohridski, Faculty of Medicine, Sofia, Bulgaria, Sofia, Bulgaria, ⁵Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ⁶Balikesir University, Faculty of Medicine, Balikesir, Türkiye, Balikesir, Turkey, ⁷Akdeniz University, Faculty of Medicine, Antalya, Türkiye, Istanbul, Turkey, ⁸Gazi University, Department of Emergency Medicine, Ankara, Türkiye, Ankara, Turkey, ⁹Hacettepe University, Faculty of Medicine, Ankara, Türkiye, Ankara, Turkey, ¹⁰Richmond University Medical Center, Department of Internal Medicine, Staten Island, NY
Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a late-onset, monogenic autoinflammatory disorder driven by somatic mutations in the UBA1 gene of hematopoietic…
Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Elise Herardot¹, Nadine Soliman¹, Audrey Pigenet¹, Ilana Slotine¹, Anni Herranan², Samia Bahieddine¹, Jean-Baptiste Fini², Olivier Tabary¹, Adeline Cambon³, Xavier HOUARD⁴, Francis BERENBAUM⁵, SELLAM JEREMIE⁶ and Alice Courties⁷, ¹Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, Paris, France, ²UMR ⁷²²¹, Phyma, CNRS–Muséum National d’Histoire Naturelle, Sorbonne Université, ⁷⁵⁰⁰⁵ Paris, France, Paris, France, ³Department of Orthopedic, Trauma and Hand Surgery, Hôpital Saint-Antoine, Sorbonne University, ¹⁸⁴ Rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France, ⁴Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ⁶Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹², Paris, France / Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
Abstract Number: 1315 • ACR Convergence 2025
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
Kale Mayor¹, Joey Mercier¹, Yuxi Long², David Robinson¹, Pingzhao Hu², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Western University, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune polyarthritis that typically affects the small joints of the hands and feet. While imaging modalities such as ultrasound…
Abstract Number: 1107 • ACR Convergence 2025
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Laura Cappelli¹, Namrata Singh², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Pankti Reid¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Clifton Bingham¹⁵ and Ami Shah¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Washington, Bellevue, WA, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Chicago Medical Center, Chicago, IL, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins University, Baltimore, MD, ¹⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Large, multi-center efforts are needed to optimally study rheumatic immune-related adverse events (rh-irAEs) from immune checkpoint inhibitor (ICI) use. We aimed to characterize the…
Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
May-Linda Lepage¹, Patrick Nolain¹, Céline Cottereaux¹, Emilie Lagoutte¹, Justine Dao¹, Adrien Cosson¹, Laetitia Furio¹, Willem Hettema², Chantal Tasset³, Roland Blanqué¹, Isabelle Parent¹ and René Galien¹, ¹Galapagos SASU, Paris, France, ²Galapagos B.V., Leiden, Netherlands, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
Abstract Number: 0439 • ACR Convergence 2025
Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
Blanche QUERE¹, Grégoire CORMIER², LE GOFF Benoit³ and Adrien LE PLUART⁴, ¹CHU de Nantes, Nantes, Pays de la Loire, France, ²Centre Hospitalier département de Vendée, La Roche Sur Yon, France, ³CHU Nantes, Nantes, France, ⁴CHU Nantes, Nantes, Pays de la Loire, France
Background/Purpose: Despite advances in therapeutic strategies, a subset of patients with rheumatoid arthritis (RA) continues to experience persistent symptoms. In 2022, the EULAR proposed a…
Abstract Number: 0127 • ACR Convergence 2025
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
Wenying Liang¹, Qinmengge Li², Jacqueline Madison¹, Ran Jing¹, Emily Chong¹, Yiran Shen¹, Rachael Bogle³, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Ajay Tambralli¹, Yu (Ray) Zuo¹, Johann Gudjonsson¹, Hui Shi⁵, Pei-Suen Tsou¹, Alex Tsoi³ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Temperance, MI, ⁵Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…
Abstract Number: 0058 • ACR Convergence 2025
Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
Richard Bell¹, Mary Huang¹, Claire Weigert², Ruoxi Yuan², Toolika Singh², Seda Seren² and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York
Background/Purpose: Disease flares, or episodic escalating inflammation, is a hallmark of autoimmune diseases, like Rheumatoid Arthritis (RA). They are particularly hard to predict and treat…
Abstract Number: 2451 • ACR Convergence 2025
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Amy Hurst¹, Mehrnaz Gharaee-Kermani¹, Yuli Cai², Rachael Bogle³, Lin Zhang¹, Amber Young², Craig Dobry¹, Srilakshmi Yalavarthi¹, Jason S. Knight¹, Johann Gudjonsson², Alex Tsoi³, Patricia Rohan⁴, Angela Kibiy⁵, Karen Boyle⁶, Margie Byron⁷, Laura Baird⁷ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Holland, OH, ⁴NIH, Bethesda, MD, ⁵NIH/NIAID, Rockville, MD, ⁶Rho, Inc, Durham, NC, ⁷Rho, Inc., Durham, NC
Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…
Abstract Number: 2043 • ACR Convergence 2025
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Büşra Fırlatan Yazgan¹, Gözde Sevgi Kart bayram¹, Buğu Bulat¹, Levent Kılıç¹, Tolga Yildirim², Umut Kalyoncu¹, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Seref Rahmi Yilmaz² and Omer Karadag³, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Division of Nephrology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Background/Purpose: Canakinumab, an interleukin-1β inhibitor, has demonstrated efficacy in treating colchicine-resistant/intolerant familial Mediterranean fever (FMF). This study aims to assess the efficacy and safety of…
Abstract Number: 1711 • ACR Convergence 2025
Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis
Andrew McGucken¹, Flavia Sunzini², Kristian Stefanov¹, Joel Parkinson¹, Salim Al-Wasity¹, John McLean¹, Gordon Waiter³, Stefan Siebert¹ and Neil Basu⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Glasgow University, Glasgow, United Kingdom, ³University of Aberdeen, Aberdeen, United Kingdom, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Fatigue is a pervasive and burdensome symptom for people with psoriatic arthritis (PsA). The mechanisms underlying PsA related fatigue are unknown. In other clinical…
Abstract Number: 1305 • ACR Convergence 2025
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
Nina Shirman¹, Liora Harel², Gil Amarilyo³, Kfir Kaidar⁴, Yonatan Butbul Aviel⁵, Merav Heshin Bekenstein⁶, Mohamad Hamad Saied⁷, Ofra Goldzweig⁸, Adi Miler⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israe, Tel Aviv, Israel, ²Schneider Children's Medical center, Nettnja, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴Pediatric rheumatology, Schneider children's medical center of Israel, Petah Tikva, Israel, ⁵Pediatric rheumatology, Technion Faculty of Medicine, Haifa, Israel, ⁶Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ⁷Carmel Medical Centre, Technion Faculty of Medicine, Haifa, Israel, ⁸Pediatric rheumatology unit, Kaplan medical canter, Rehovot, Israel, ⁹Pediatric rheumatology unit, Technion Faculty of Medicine, Haifa, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is an autoinflammatory disease following SARS-CoV-2 exposure. The optimal treatment strategy remains under investigation, though intravenous immunoglobulin (IVIG)…
Abstract Number: 1101 • ACR Convergence 2025
Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Heba Altarawneh¹, Gregory Challener², Mazen Nasrallah³, Janeth Yinh⁴, Hyon K. Choi⁵ and Minna Kohler⁶, ¹Mass General Hospital, Boston, MA, ²MGH, Boston, MA, ³MGB-Salem Hospital, Lynn, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitor (ICI)–associated arthritis has been classified into distinct phenotypes, including inflammatory arthritis (IA), polymyalgia rheumatica (PMR)-like syndrome, activated crystalline arthritis, and activated…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 0437 • ACR Convergence 2025
Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention
Anokhi Saklecha¹, Amelia Khoo², Sierra Mendelsohn², Abhijeet Danve³, Mei Xue Dong⁴ and Lisa Suter², ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Yale-New Haven Medical Center, new haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 1.5 to 2 fold increased risk of cardiovascular disease (CVD) due to systemic inflammation and endothelial dysfunction.…

« Previous Page
1
…
5
6
7
8
9
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].